2024
The Use of Biologic Agents for the Treatment of Cutaneous Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Review of Reported Cases
Pach J, Valido K, Belzer A, Leventhal J. The Use of Biologic Agents for the Treatment of Cutaneous Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Review of Reported Cases. American Journal Of Clinical Dermatology 2024, 25: 595-607. PMID: 38767827, DOI: 10.1007/s40257-024-00866-z.Peer-Reviewed Original ResearchCutaneous immune-related adverse eventsImmune-related adverse eventsAdverse eventsAntitumor responseBiological agentsHigh-dose systemic corticosteroidsSevere cutaneous adverse reactionsImmune checkpoint inhibitorsStevens-Johnson syndromeCutaneous adverse reactionsAdverse event patternEnglish-language literatureTransient acantholytic dermatosisTreating high-gradeSpectrum of dermatologic manifestationsCheckpoint inhibitorsSystemic corticosteroidsCorticosteroid-sparingImmunobullous disordersPsoriasiform eruptionLichenoid reactionsEczematous dermatitisLichenoid eruptionDermatological manifestationsHigh-grade
2018
Bullous disorders associated with anti–PD-1 and anti–PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy
Siegel J, Totonchy M, Damsky W, Berk-Krauss J, Castiglione F, Sznol M, Petrylak DP, Fischbach N, Goldberg SB, Decker RH, Stamatouli AM, Hafez N, Glusac EJ, Tomayko MM, Leventhal JS. Bullous disorders associated with anti–PD-1 and anti–PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy. Journal Of The American Academy Of Dermatology 2018, 79: 1081-1088. PMID: 30025829, DOI: 10.1016/j.jaad.2018.07.008.Peer-Reviewed Original ResearchMeSH KeywordsAdrenal Cortex HormonesAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalB7-H1 AntigenDrug EruptionsFemaleHumansLichenoid EruptionsMaleMiddle AgedNeoplasm ProteinsNeoplasmsNivolumabPemphigoid, BullousProgrammed Cell Death 1 ReceptorRetrospective StudiesSkin Diseases, VesiculobullousTertiary Care CentersTreatment OutcomeConceptsPD-L1 therapyAnti-PD-1/PD-L1 therapyBullous disordersBullous eruptionPD-1/PD-L1 therapyCell death ligand-1 therapyAnti-programmed cell death 1Cancer therapyDeath ligand 1 therapySingle tertiary care centerLinear IgA bullous dermatosisYale-New Haven HospitalDistinct therapeutic challengesInterruption of immunotherapyPositive tumor responseSteroid-sparing agentTertiary care centerIgA bullous dermatosisCell death 1New Haven HospitalStable diseaseSystemic corticosteroidsSystemic steroidsMaintenance therapyL1 therapy
2012
Is it time to re-evaluate the treatment of pemphigus?
Leventhal JS, Sanchez MR. Is it time to re-evaluate the treatment of pemphigus? Journal Of Drugs In Dermatology 2012, 11: 1200-6. PMID: 23134985.Peer-Reviewed Original ResearchConceptsIntravenous immunoglobulinCorticosteroid-related adverse effectsAdverse effectsTreatment of pemphigusCost of therapySerious adverse effectsManagement of pemphigusBest practice treatmentSystemic corticosteroidsClinical improvementMost patientsMucocutaneous diseaseStandard therapyBiologic agentsImmunosuppressive agentsPemphigus vulgarisBody of evidenceRecent trialsFatal infectionNovel therapiesTherapeutic strategiesPemphigusTherapyRemissionTreatment
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply